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Emerging Infections Program Network Report
 
Methicillin-Resistant Staphylococcus aureus, 2015
 
EIP Areas
California (3 county San Francisco Bay area); Connecticut; Georgia (8 county Atlanta area); Minnesota (2 metro Twin City counties); New York (1
Rochester county); Tennessee (1 Nashville county).
Note: The population under surveillance changed from 2014; it was reduced by 10 counties located in 3 states.
Population
The surveillance areas represent 14,402,040 persons
 
Source: National Center for Health Statistics bridged-race vintage 2015 postcensal file.

Case Definition
Invasive methicillin-resistant Staphylococcus aureus (MRSA) disease:  isolation of MRSA from a normally sterile site in a resident of the surveillance
area in 2015. Cases of disease are classified into one of three epidemiologic classifications. A case is classified as hospital-onset (HO) if the MRSA
culture was obtained on or after the fourth calendar day of hospitalization, where admission is hospital day 1;  as healthcare-associated community-
onset (HACO) if the culture was obtained in an outpatient setting or before the fourth calendar day of hospitalization and had one or more of the
following: 1) a history of hospitalization, surgery, dialysis, or residence in a long term care facility in the previous year, or 2) the presence of a central
vascular catheter (CVC) within 2 days prior to MRSA culture; and as community-associated (CA) if none of the previously mentioned criteria are met.
Methodology
EIP personnel routinely contacted all microbiology laboratories serving healthcare facilities in their area to identify cases. Standardized case report
forms that include information on demographic characteristics, clinical syndrome, and outcome of illness were completed for each identified case.
Convenience samples of isolates were collected and sent to CDC for routine testing, including antimicrobial susceptibility testing, toxin testing,
SCCmec typing, and spa typing. Pulsed field gel electrophoresis (PFGE) of all isolates was discontinued in 2008; up until 2012, PFGE was inferred based
on a validated algorithm (http://www.cdc.gov/HAI/settings/lab/inferred-PFGE-algorithm.html). Starting in 2012, spa typing was added to the routine 
laboratory testing.  Pulsed field type is currently inferred based on spa type, inferred MLST clonal complex and molecular characteristics of the isolates
(http://www.cdc.gov/HAI/settings/lab/CCalgorithm.html). In 2015, isolates were only collected in three sites (Georgia, Minnesota, and Tennessee).
Regular laboratory audits were performed to ensure completeness of case detection.
In 2015, some sites collected limited data from most hospital-onset cases, with full case report form data collected only for a random sample of 10– 
25% of hospital-onset cases. Data not collected because of sampling were estimated based on the distribution of collected data to calculate
incidence.  Detailed case data below only reflect data from full case report forms unless otherwise specified. Rates of invasive MRSA disease among 
all patients were calculated using population estimates for 2015. Cases with unknown race were assigned race based on distribution of known age,
race, and gender by EIP site.
Rates of invasive MRSA disease among patients who were undergoing chronic dialysis treatment were calculated using the December 31, 2014 point
prevalent counts of patients on dialysis from the United States Renal Data System (USRDS) (http://www.usrds.org/adr.htm).   
Results
Reported Race among 2,705 Cases Cases, Deaths & Inferred PFGE Type by Epidemiological Classification




Unknown race (n=321) distributed amongst known
a Cases per 100,000 population for EIP areas (crude rates)
Reported Cases on Chronic Dialysis (n=365) 








aTwo patients had AV Fistula/Graft and CVC
No. (%) Inferred PFGE Type
USA500/MRSA No. (Rate) No. (Rate)  Total N USA100 USA300 IberianClass Cases b Deaths c 
CA 560 (3.9) 53 (0.4) 85 8(9.4) 56 (65.9) 5 (5.9)
HCA a 2117 (14.8) 279 (1.9) 372 141 (37.9) 124 (33.3) 59 (15.9)
HO 439 (3.1) 74 (0.5) 75 34 (45.3) 22 (29.3) 14 (18.7)
HACO 1678 (11.7) 205 (1.4) 297 107 (36.0) 102 (34.3) 45 (15.2)
a HCA: Healthcare-associated invasive MRSA infection; sum of patients that are classified 
as either the HO or HACO classes
b n= 28 epidemiologic category unknown
c n=2 epidemiologic category unknown. HO rate imputed from a sample of cases.
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Reported Clinical Syndrome by Epidemiological Class
CA HACO HO
Syndrome a (n=560) (n=1678) (n=133)
No. (%) No. (%) No. (%)
Bloodstream Infection b
with other syndrome 343 (61.3) 946 (56.4) 47 (35.3)
with no other syndrome 87 (15.5) 495 (29.5) 62 (46.6)
Pneumonia 72 (12.9) 220 (13.1) 19 (14.3)
Osteomyelitis 98 (17.5) 241 (14.4) 13 (9.8)
Endocarditis 56 (10.0) 93 (5.5) 2 (1.5)
Cellulitis 140 (25.0) 178 (10.6) 12 (9.0)
Wounds
Surgical c 9 (1.6) 113(6.7) 2 (1.5)
Decubitus/Pressure Ulcers 10 (1.8) 60(3.6) 1 (0.8)
Skin Abscesses d 63 (11.3) 69(4.1) 2 (1.5)
Other Wounds e 13 (2.3) 89(5.3) 1 (0.8)
Traumatic 2 (0.42) 3(0.2) 0 (0.0)
a Some case patients had more than one syndrome.
 
b Catheter site infection or AV fistula infection only are included in BSI with other syndrome.
 
c Combines deep tissue/organ infection and infection of a surgical wound, post operatively.
 
d Category includes skin abscess, necrotizing fasciitis, gangrene.
 
e Category includes non-traumatic and other chronic wound infections.
 
Number and Incidence Rates of Invasive MRSA Infections by Dialysis Status and Epidemiologic Category
Epidemiologic Dialysis Status
Category Non-Dialysis Patientsa Dialysis Patientsb Totala
2014e 2015 2014e 2015 2014e 2015
No. Incidence No. Incidence No. Incidence No. Incidence No. Incidence No. Incidence 
Rate Rate Rate Rate Rate Rate
CA 692 4.9 560 3.9 0 0 0 0 692 4.9 560 3.9
HCA 1875 13.2 1695 11.8 472 1637.9 422 1478.6 1866 16.5 2117 14.8
HO 443 3.1 378 2.6 38 137.5 61 213.7 481 3.4 439 3.1
HACO 1432 10.1 1317 9.2 434 1570.4 361 1264.9 1866 13.1 1678 11.7
Overallc 2589 18.9 2283 15.9 472 1707.9 422 1478.7 3061 21.5 2705 18.8
a Incidence (no. per 100,000 population per year) are calculated using 2014 and 2015 US Census Data.

bIncidence (no. per 100,000 dialysis patients per year) for dialysis patients are calculated using 2013 and 2014 USRDS point prevalence data.

c Non-dialysis and dialysis estimated number and incidence based on data from a sample of HO cases.
 
d38 cases could not be classified into an epidemiological category or category is unknown and therefore are counted in the overall estimate only
 


























Incidence of Invasive MRSA, by Epidemiological
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Discussion
Surveillance data from 2015 represents the eleventh full year of performing population-based surveillance for invasive MRSA infections through 
the Emerging Infections Program. Compared to 2014, incidence of invasive HCA MRSA decreased by 10%.
Beginning in 2015, MRSA targets for the HHS Action Plan are calculated using a different methodology and are no longer included in this report.
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